Stay updated on Medicenna Therapeutics Press Releases

Sign up to get notified when there's something new on the Medicenna Therapeutics Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the Medicenna Therapeutics Press Releases page

  1. Check
    today
    Change Detected
    Summary
    The news-release list now includes Medicenna’s second-quarter fiscal 2027 financial results and an update on Bizaxofusp survival outcomes in glioblastoma. Older releases about the ABILITY-1 presentation and the shareholder meeting are no longer listed.
    Difference
    3%
    Check dated 2026-11-22T02:33:36.000Z thumbnail image
  2. Check
    7 days ago
    Change Detected
    Summary
    Medicenna’s news list adds a November 9, 2026 release presenting ABILITY-1 results at SITC 2026, reporting a 40% ORR in biomarker-enriched gastrointestinal cancer patients resistant to approved therapies. The September 24 announcement about presenting bizaxofusp results at a neuro-oncology meeting is no longer listed.
    Difference
    3%
    Check dated 2026-11-15T03:00:00.000Z thumbnail image
  3. Check
    14 days ago
    Change Detected
    Summary
    Medicenna’s news releases now include a November 4, 2026 announcement of ABILITY-1 enrollment completion and a webinar on updated MDNA11 results. The September 3, 2026 announcement about a conference appearance is no longer listed.
    Difference
    4%
    Check dated 2026-11-08T05:18:41.000Z thumbnail image
  4. Check
    21 days ago
    Change Detected
    Summary
    Medicenna’s news-release list now features an October 26, 2026 announcement reporting CD122 blockade and extended survival with MDNA209 in preclinical autoimmune disease models. The August 14, 2026 release on first-quarter fiscal 2027 financial results and upcoming conference presentations is no longer listed.
    Difference
    3%
    Check dated 2026-11-01T02:22:24.000Z thumbnail image
  5. Check
    28 days ago
    Change Detected
    Summary
    A new October 22, 2026 news release announces Medicenna’s planned presentation of preclinical data on its CD122 superantagonist MDNA209. The June 26, 2026 fiscal-year results and operational-highlights release is no longer listed.
    Difference
    3%
    Check dated 2026-10-25T02:24:12.000Z thumbnail image
  6. Check
    42 days ago
    Change Detected
    Summary
    The news releases list now features Medicenna’s October 5, 2026 announcement of an oral presentation of topline ABILITY-1 study data at SITC 2026. The June 11, 2026 release about newly issued and allowed patents has been removed from the displayed list.
    Difference
    3%
    Check dated 2026-10-11T03:13:32.000Z thumbnail image

Stay in the know with updates to Medicenna Therapeutics Press Releases

Enter your email address, and we'll notify you when there's something new on the Medicenna Therapeutics Press Releases page.